For many women, migraine follows a hormonal pattern that begins in adolescence, worsens in the lead-up to menstrual periods, and then — during perimenopause — becomes significantly more frequent and harder to manage.
If your migraines got worse in your late 30s or 40s, or if attacks that used to be predictable and manageable have become more frequent and unpredictable, you're not imagining it. The hormonal changes of perimenopause are one of the most well-documented drivers of migraine worsening.
What perimenopause does to migraine
Migraine is strongly linked to estrogen. More precisely, it's linked to estrogen fluctuation — the rise and fall of estrogen levels is a more reliable trigger than absolute estrogen levels.
During the reproductive years, estrogen fluctuates on a monthly cycle. Many women with migraine experience their worst attacks in the days before menstruation, when estrogen drops sharply — a pattern called menstrual migraine.
Perimenopause amplifies this pattern dramatically. As the ovaries become less predictable in their hormone production, estrogen levels stop following the regular monthly cycle and begin fluctuating erratically — sometimes swinging significantly day to day. For migraine patients, this erratic estrogen environment is like having a migraine trigger that's constantly active.
The result: migraine frequency often increases. Attacks may become less predictable and harder to preempt. Medications that worked reliably before may seem less effective, partly because attacks are coming more frequently and from a broader range of triggers.
This is distinct from menopause itself
It's worth distinguishing perimenopause from menopause. Menopause — the point at which menstruation has stopped for 12 months — is actually associated with improvement in migraine for many women, because estrogen levels stabilize at a lower but consistent level.
Perimenopause, which can last 4-10 years before menopause, is the difficult period. The unpredictable hormonal fluctuation during perimenopause is what drives the worsening, not menopause itself.
Post-menopausal women often find their migraines improve. Getting through perimenopause with adequate treatment is the challenge.
What changes about treatment in perimenopause
The hormonal dimension of perimenopausal migraine doesn't change the fundamentals of treatment — CGRP therapy, triptans, and gepants remain the most effective interventions. But it adds important considerations:
Preventive treatment becomes more important. If episodic migraines (fewer than 15 days per month) worsen into more frequent attacks during perimenopause, preventive therapy becomes appropriate when it might not have been before. CGRP biologics, which prevent migraines by blocking the CGRP pathway, are effective regardless of hormonal trigger.
Hormonal management is worth discussing. Some women find that stabilizing estrogen levels through low-dose hormonal therapy reduces the estrogen fluctuation that drives perimenopausal migraine. This requires careful clinical evaluation — some forms of hormonal therapy can worsen migraine in some patients — but for the right patient with the right clinical picture, it can be a significant intervention.
Triptans and cardiovascular risk. As women enter their 40s and 50s, cardiovascular risk assessment becomes part of the conversation around triptan use. Most women in perimenopause without cardiovascular risk factors can continue using triptans safely, but this is worth discussing explicitly with a clinician.
The "it's just hormones, wait it out" problem
One of the most common and most frustrating responses perimenopausal migraine patients encounter from clinicians is some version of "your hormones are just changing — let's see how things look after menopause."
This is clinically inadequate. Perimenopause can last nearly a decade. Effective treatments exist. Telling a patient with 15-20 migraine days per month to wait it out is not a treatment plan.
If you're in perimenopause and your migraines have worsened, you deserve a clinician who takes the hormonal picture seriously, is familiar with the current evidence for CGRP therapy in this population, and builds a treatment plan that accounts for where you are in your hormonal transition.
What Wellday offers for perimenopausal migraine patients
Wellday's clinical approach takes the hormonal dimension of migraine seriously. During your consultation, your clinician will assess your migraine pattern including hormonal triggers, your current menopausal status, and your full clinical picture.
For women whose migraine frequency has increased during perimenopause and who meet criteria for preventive treatment, CGRP therapy is often the most effective single intervention. We handle the prior authorization and savings card coordination that makes these medications accessible.
We're also building toward expanded women's health services that will address the broader hormonal health picture — perimenopause, HRT, and the intersection of women's health and neurological wellbeing. If you'd like to be among the first to know when those services launch, building your migraine profile is the first step.
For now: if your migraines have worsened and you're in your late 30s, 40s, or early 50s, the hormonal connection is real, the treatments are effective, and you don't have to wait it out.